Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FORAY: A Phase 2, Randomized, Open-Label Study Evaluating Vepugratinib in Adults With FGFR3 Altered Low Grade, Intermediate Risk, Non-muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

NCT07827612 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07827612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07827612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FORAY: A Phase 2, Randomized, Open-Label Study Evaluating Vepugratinib in Adults With FGFR3 Altered Low Grade, Intermediate Risk, Non-muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
March 31, 2031
Enrollment
161 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

receptor, fibroblast growth factor, type 3, urinary bladder neoplasms, urologic neoplasms